Browsing Tag
ZIIHERA
6 posts
Zymeworks gets $250m boost after Ziihera wins major first-line cancer approval
FDA expands Ziihera into first-line HER2-positive gastroesophageal cancer, unlocking $250 million for Zymeworks. See why the approval matters.
Jazz Pharmaceuticals raises $1.1bn at 1.875% while repurchasing $225m of stock
Jazz Pharmaceuticals has priced $1.1 billion of 1.875% exchangeable notes due 2032, generating about $1.08 billion of net proceeds while concurrently repurchasing $225 million of shares.
Ziihera FDA approval unlocks $250m for Zymeworks as Jazz expands HER2 drug into first-line gastric cancer
The FDA has approved two Ziihera-based first-line regimens for HER2-positive advanced gastroesophageal adenocarcinoma, triggering a $250 million payment to Zymeworks and giving Jazz a much larger commercial opportunity.
Zymeworks (ZYME) to buy Theravance (TBPH) for $929m in cash plus ampreloxetine CVR
Zymeworks (ZYME) to acquire Theravance (TBPH) for $17/share plus CVR, $929M equity value. Non-recourse OMERS financing minimises ZYME's cash at risk.
Jazz Pharmaceuticals (JAZZ) builds $4bn oncology option through AbCellera partnership
Jazz could pay AbCellera more than $4 billion across five oncology programmes. Read how the option deal reshapes JAZZ and ABCL growth strategies.
BeOne Medicines wins FDA Priority Review for TEVIMBRA in HER2-positive GEA as ONC stock faces trial-to-approval test
BeOne has survival data and FDA momentum. The bigger question is whether TEVIMBRA can change first-line HER2-positive GEA care.